TrioBiotics Pharma AG
Triton Biopharma AG: Dr. Stephan Eschmann is appointed to the Board of Directors of Triton BioPharma A
Triton Biopharma AG / Change of Personnel Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Frankfurt Stock Exchange Symbol – 4ON December 22, 2008 Dr. Stephan Eschmann is appointed to the Board of Directors of Triton BioPharma AG ZUG, Switzerland – December 22, 2008 – TRITON BIOPHARMA AG (Frankfurt: 4ON) today announced the appointment of Dr. Stephan Eschmann to the Board of Directors for Triton BioPharma AG. Dr. Eschmann began his professional legal career as barrister, and then became a member of the legal department of VITA life insurance company, known today as Zurich life. Years later, he moved on to join the legal department of the Swiss Bank Corporation, known today as UBS. In 1990, Dr. Eschmann established his own law firm, advising clients in a variety of financial matters including equity investment, mergers & acquisitions, IPO’s, international trade and financing, fund raising, venture capital and taxation. Dr. Stephan Eschmann was educated at the University of Zurich and obtained a law degree in 1977. He was admitted to the Bar in Zurich in 1979 and further obtained a doctorate degree in law at the University of Zurich in 1984. 'Triton is very pleased to have Dr. Eschmann as a Board member. His participation in the Board will be an important asset as he brings both legal expertise and an understanding of the European financial markets.' said Angelo Boujos, Chairman and CEO of Triton BioPharma AG. About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton’s biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. Triton’s current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. Contact: Investor Relations Europe: Milestone Media AG, Zug, Switzerland Phone: +41 (0)41 5000 769 Fax: +41 (0)41 5000 728 E-mail: info@milestonemedia.ch For more information, visit www.tritonbiopharma.com 22.12.2008 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found